Evaluation of Commercial Immunoassays for Detection of Antibody against *Helicobacter pylori* in Thai Dyspeptic Patients

Orrawadee Hanvivatvong,1* Atinop Pongpanich, 1 Duangporn Thong-Ngam,2 Niramol Thammacharoenrach,1 and Pinit Kullavanijaya 3

Department of Microbiology, 1 Department of Physiology, 2 and Department of Medicine, 3 Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Received 16 October 2003/Returned for modification 12 December 2003/Accepted 12 February 2004

The performance of five immunoassays for detection of immunoglobulin G antibody against *Helicobacter pylori* in 191 dyspeptic patients was evaluated. The sensitivities, specificities, accuracies, positive predictive values, and negative predictive values ranged from 86.32 to 97.89%, 57.95 to 72.22%, 77.02 to 83.76%, 71.54 to 77.42%, and 83.33 to 96.23%, respectively. The immunoglobulin A test kit also gave a high sensitivity and negative predictive value (95.79 and 91.40%, respectively), while the specificity was relatively low (51.14%).

Serological assay for *Helicobacter pylori* antibody is a noninvasive method to detect *H. pylori* infection. It has been reported to have sensitivity and specificity in predicting the status of *H. pylori* infection in untreated patients as accurately as invasive tests (11, 12). However, it has been suggested that serological tests for *H. pylori* should be locally validated (7), because assays validated in one region may yield variable diagnostic performances in others. These variations may be attributed to many factors, including the source of antigen used, the prevalence of infection in each population studied, and the reference method used to determine true *H. pylori* infection status. Therefore, reevaluation is needed before implementing a test in different populations. In Thailand, the seroprevalence of *H. pylori* infection has been reported to be higher than that in industrialized countries (10), and commercially available enzyme immunoassay (EIA) test kits have been reported to have lower sensitivities and specificities compared to in-house EIAs in Thai dyspeptic patients (1). We therefore evaluated the performance of five commercial test kits for detecting of immunoglobulin G antibody against *H. pylori*. Three of them use a standard enzyme-linked immunosorbent assay (Cobas Core anti-*H. pylori* EIA [Roche, Mannheim, Germany]); Pyloriset EIA-GIII [Orion, Espoo, Finland]; and Enzygnost anti-*H. pylori* II/IgG [Dade Behring, Marburg, Germany]), and two are rapid assay test kits (Pyloriset Dry [Orion] and anti-*H. pylori* IgG Immunocomb [Oregenics, Yavne, Israel]). One *H. pylori* IgA antibody test kit (Pyloriset EIA-AIII) was also evaluated.

A total of 191 patients (57 males and 134 females; age range, 16 to 83 years [mean, 39 years]) were studied. Endoscopy was performed in all patients, and 183 (95.81%) of them were diagnosed as having nonulcer dyspepsia while the remaining 8 patients (4.19%) had a duodenal ulcer. Patients who received antibiotic therapy, bismuth treatment, or a proton pump inhibitor or H2 blocker within 1 month prior to the study were excluded. Written informed consent was obtained from all patients before the study. Five milliliters of clotted blood was obtained on the day of endoscopy. Sera were kept at −20°C until analyzed. The biopsy specimens from the antrum and stomach body were obtained for rapid urease (CLO) test and histological and cultural examination. All the tests were performed according to the manufacturer’s instructions and without the knowledge of the status of the patient’s infection. The results of these examinations were described previously (4).

In this study, a patient was considered infected with *H. pylori* when either culture was positive or both rapid urease (CLO) test and histological analysis were positive. Statistic analyses for sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were calculated against the status of *H. pylori* infection. As shown in Table 1, the three standard EIAs for IgG antibody gave a similar higher sensitivity (95.95 to 97.89%) and negative predictive value (92.06 to 96.23%) when compared to the rapid immunoassays. The specificity of all tests was considered low (57.95 to 69.57%), while the accuracy was similar, with the highest at 83.76% by Cobas Core anti-*H. pylori* EIA. The agreement between each test as analyzed by kappa statistic was relatively high among the standard immunoassays. Pyloriset Dry gave the lowest agreement with other tests, especially with Immunocomb (Table 2).

As reported by other investigators who have found that Western antigen-based serology has relatively poor performance with samples from Asian groups (5, 6, 8), we also found a low specificity of these tests in our study. The possible reasons may be due to the high prevalence rate of *H. pylori* infection in the Thai population (10). Therefore, the presence of antibody in some sera may reflect past infection. Furthermore, the results of validation are highly dependent on the reliability of the reference method used, and it is generally accepted that all the tests for *H. pylori* have their pitfalls and limitations that may affect the status of infection. In this study, the status of infection depended on the results of culture or histology and rapid urease (CLO) test. We observed that 10 out of 35 seropositive (as demonstrated by at least two serological tests used in this study) patients in the 92 noninfected groups were concomitantly positive by histology or urease test. Most of them had higher antibody levels than those who were...
positive by serology alone, as shown in Fig. 1. Therefore, it is possible that some patients of the group may have had \textit{H. pylori} infection during the study period. Figure 1 also demonstrates the distribution of \textit{H. pylori} IgG antibody levels in the \textit{H. pylori}-infected and noninfected patients.

The performance of the rapid tests was similar to that reported previously (2) in that they were slightly inferior to the standard EIA tests. Although better results have also been reported (9, 14), the use of rapid tests has not been recommended (7). However, these tests are easy to perform and can be finished within a few minutes without the need of sophisticated equipment. By using these tests and with careful interpretation, the physician can determine \textit{H. pylori} infection of a patient at the first consultation.

Anti-\textit{H. pylori} IgA antibody was found in 91 out of 95 (95.79\%) \textit{H. pylori}-infected patients (Table 1). Almost all, except one, were also found to have IgG antibody (by Pyloriset EIA-GIII) in their serum. Combining the results of this Pyloriset EIA-AIII and Pyloriset EIA-GIII slightly increased the sensitivity and the negative predictive value, but the specificity was markedly decreased (data not shown). Although anti-\textit{H. pylori} IgA antibody has been reported to have diagnostic values

<table>
<thead>
<tr>
<th>Kit</th>
<th>No. tested</th>
<th>No. of \textit{H. pylori}-positive (No. of true positive)</th>
<th>No. of \textit{H. pylori}-negative (no. of true negative)</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>Accuracy (%)</th>
<th>Positive predictive value (%)</th>
<th>Negative predictive value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cobas Core anti-\textit{H. pylori} EIA</td>
<td>191</td>
<td>124 (99)</td>
<td>67 (92)</td>
<td>96.97</td>
<td>95.95</td>
<td>98.39</td>
<td>77.42</td>
<td>95.52</td>
</tr>
<tr>
<td>Enzygnost anti-\textit{H. pylori} II/IgG</td>
<td>191</td>
<td>129 (99)</td>
<td>62 (92)</td>
<td>95.95</td>
<td>63.64</td>
<td>80.64</td>
<td>73.44</td>
<td>92.06</td>
</tr>
<tr>
<td>Pyloriset EIA-G III</td>
<td>183</td>
<td>130 (95)</td>
<td>53 (88)</td>
<td>97.89</td>
<td>57.95</td>
<td>78.69</td>
<td>71.54</td>
<td>96.23</td>
</tr>
<tr>
<td>Anti-\textit{H. pylori} IgG Immunocomb</td>
<td>161</td>
<td>111 (86)</td>
<td>50 (75)</td>
<td>93.02</td>
<td>58.67</td>
<td>77.02</td>
<td>72.07</td>
<td>88.00</td>
</tr>
<tr>
<td>Pyloriset Dry</td>
<td>185</td>
<td>107 (95)</td>
<td>78 (90)</td>
<td>86.32</td>
<td>72.22</td>
<td>78.46</td>
<td>76.64</td>
<td>83.33</td>
</tr>
<tr>
<td>Pyloriset EIA-A III</td>
<td>183</td>
<td>134 (95)</td>
<td>49 (88)</td>
<td>95.79</td>
<td>51.14</td>
<td>74.32</td>
<td>67.91</td>
<td>91.40</td>
</tr>
</tbody>
</table>

\textsuperscript{a} Numbers of true positive and true negative were determined by the results of culture or CLO test and histology.

FIG. 1. Distribution of anti-\textit{H. pylori} IgG antibody levels in \textit{H. pylori}-infected and uninfected patients ($n = 191$). Results of the Cobas Core anti-\textit{H. pylori} EIA test, with serum antibody levels of $<6$ U/ml, were considered negative.
when used in conjunction with IgG (3, 13), we agree with a previous report (12) that IgA had no additional diagnostic value in our clinical settings.

With regards to the high sensitivity and negative predictive values of the commercial H. pylori IgG antibody kits used in this study, we concluded that, with careful interpretation, these tests may be used as an alternative test for determining H. pylori infection, especially in those for whom gastroscopy cannot be performed.

We thank Science Tech Co., Ltd., Bangkok, Thailand; Roche Diagnostic, Ltd., Bangkok, Thailand; Firmer Co., Ltd., Bangkok, Thailand; and Dade Behring, Bangkok, Thailand, for their support with the test reagents.

REFERENCES